214 related articles for article (PubMed ID: 30936346)
1. Waldenstrom-associated anti-MAG paraprotein polyneuropathy with neurogenic tremor.
Canepa C
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30936346
[TBL] [Abstract][Full Text] [Related]
2. [Polyneuropathy involving cranial nerves associated with monoclonal IgM antibodies with anti-MAG/SGPG/SGPLG/sulfatides activity].
Drouet A; Caudie C; Vallat JM; Ruel JH; Felten D; Guilloton L; Giraud P
Rev Neurol (Paris); 2006 Jun; 162(6-7):760-6. PubMed ID: 16840988
[TBL] [Abstract][Full Text] [Related]
3. IgM paraprotein and anti-MAG sensory polyneuropathy associated with Waldenstrom's macroglobulinaemia and medullary carcinoma of the thyroid.
Yang Y; Canepa C
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33622752
[TBL] [Abstract][Full Text] [Related]
4. [Rapid improvement by rituximab treatment in a case of demyelinating polyneuropathy with anti-myelin-associated glycoprotein antibody].
Motoyama R; Yamakawa K; Suzuki S; Kusunoki S; Tanaka M
Rinsho Shinkeigaku; 2011 Oct; 51(10):761-4. PubMed ID: 22019868
[TBL] [Abstract][Full Text] [Related]
5. IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy.
Campagnolo M; Zambello R; Nobile-Orazio E; Benedetti L; Marfia GA; Riva N; Castellani F; Bianco M; Salvalaggio A; Garnero M; Ruiz M; Mataluni G; Fazio R; Ermani M; Briani C
J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1094-1097. PubMed ID: 28501820
[No Abstract] [Full Text] [Related]
6. Terminal latency index in polyneuropathy with IgM paraproteinemia and anti-MAG antibody.
Cocito D; Isoardo G; Ciaramitaro P; Migliaretti G; Pipieri A; Barbero P; Cucci A; Durelli L
Muscle Nerve; 2001 Oct; 24(10):1278-82. PubMed ID: 11562906
[TBL] [Abstract][Full Text] [Related]
7. Peripheral neuropathy as clinical onset of monoclonal IgM/k-related amyloidosis.
Briani C; Ferrari S; Berno T; Visentin A; Cacciavillani M; Cavallaro T; Fedrigo M; Rizzo S; Salvalaggio A; Trentin L; Piazza F
J Peripher Nerv Syst; 2023 Jun; 28(2):262-265. PubMed ID: 36859783
[TBL] [Abstract][Full Text] [Related]
8. [Anti-myelin-associated glycoprotein antibody positive IgM monoclonal gammopathy related peripheral neuropathy: 11 cases and literature review].
Gao XM; Jia MN; Qian M; Ren HT; Zhang L; Shen KN; Cao XX; Li J
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):901-905. PubMed ID: 31856437
[No Abstract] [Full Text] [Related]
9. Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy.
Briani C; Visentin A; Salvalaggio A; Cacciavillani M; Trentin L
Eur J Neurol; 2019 Feb; 26(2):371-375. PubMed ID: 30315672
[TBL] [Abstract][Full Text] [Related]
10. Deterioration of tremor after treatment with rituximab in anti-MAG neuropathy.
Doneddu PE; Kazmi M; Samuel M; Mahdi-Rogers M; Hadden RDM
J Neurol Sci; 2017 Feb; 373():344-345. PubMed ID: 28131219
[No Abstract] [Full Text] [Related]
11. Chronic inflammatory demyelinating polyneuropathy in Waldenström's macroglobulinemia.
Cassereau J; Letournel F; François S; Dubas F; Nicolas G
Rev Neurol (Paris); 2011 Apr; 167(4):343-7. PubMed ID: 21429544
[TBL] [Abstract][Full Text] [Related]
12. The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies.
Briani C; Visentin A; Castellani F; Cacciavillani M; Trentin L
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35798560
[TBL] [Abstract][Full Text] [Related]
13. The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies.
Briani C; Visentin A; Castellani F; Cacciavillani M; Trentin L
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35577568
[TBL] [Abstract][Full Text] [Related]
14. Anti-MAG associated cerebellar ataxia and response to rituximab.
Zis P; Rao DG; Hoggard N; Sarrigiannis PG; Hadjivassiliou M
J Neurol; 2018 Jan; 265(1):115-118. PubMed ID: 29159464
[TBL] [Abstract][Full Text] [Related]
15. Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
Castellani F; Visentin A; Schirinzi E; Salvalaggio A; Cacciavillani M; Candiotto C; Baratè C; Cellini A; Bertorelle R; Siciliano G; Trentin L; Briani C
Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37137530
[TBL] [Abstract][Full Text] [Related]
16. Neuropathy associated with immunoglobulin M monoclonal gammopathy: A combined sonographic and nerve conduction study.
Goedee HS; Notermans NC; Visser LH; van Asseldonk JH; Franssen H; Vrancken AFJE; Nikolakopoulos S; van den Berg LH; van der Pol WL
Muscle Nerve; 2019 Sep; 60(3):263-270. PubMed ID: 31269243
[TBL] [Abstract][Full Text] [Related]
17. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
Dalakas MC; Rakocevic G; Salajegheh M; Dambrosia JM; Hahn AF; Raju R; McElroy B
Ann Neurol; 2009 Mar; 65(3):286-93. PubMed ID: 19334068
[TBL] [Abstract][Full Text] [Related]
18. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
Gorson KC; Natarajan N; Ropper AH; Weinstein R
Muscle Nerve; 2007 Jan; 35(1):66-9. PubMed ID: 16967492
[TBL] [Abstract][Full Text] [Related]
19. Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy.
Amaador K; Wieske L; Koel-Simmelink MJA; Kamp A; Jongerius I; de Heer K; Teunissen CE; Minnema MC; Notermans NC; Eftimov F; Kersten MJ; Vos JMI
J Neurol; 2022 Jul; 269(7):3700-3705. PubMed ID: 35157138
[TBL] [Abstract][Full Text] [Related]
20. Chronic demyelinating neuropathy with anti-myelin-associated glycoprotein antibody without any detectable M-protein.
Sakamoto Y; Shimizu T; Tobisawa S; Isozaki E
Neurol Sci; 2017 Dec; 38(12):2165-2169. PubMed ID: 28980134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
